TGFβ1 contributes to cardiomyogenic-like differentiation of human bone marrow mesenchymal stem cells

Area of Science:

• Stem cell biology
• Cardiovascular research
• Regenerative medicine

Background:

• Mesenchymal stem cells (MSCs) are commonly differentiated into cardiomyocytes using 5-azacytidine.
• Transforming growth factor β1 (TGF-β1) shares signaling pathways with 5-azacytidine.
• Investigating TGF-β1 as an alternative inducer for cardiac differentiation in human bone marrow MSCs.

Purpose of the Study:

• To compare the efficacy of TGF-β1 with 5-azacytidine in inducing cardiac differentiation of human bone marrow MSCs.
• To evaluate the molecular and morphological characteristics of MSC-derived cardiomyocytes using both inducers.

Main Methods:

• Comparative analysis of differentiation protocols using TGF-β1 and 5-azacytidine.
• Assessment of cell morphology and cardiac marker expression via reverse transcriptase PCR, flow cytometry, and quantitative PCR.
• Evaluation of myosin light chain-2v expression as a key cardiac marker.

Main Results:

• Both TGF-β1 and 5-azacytidine induced similar morphological changes in MSCs.
• Comparable cardiac marker gene and protein expression profiles were observed under both differentiation conditions.
• Similar levels of cardiac cell-like molecular characteristics were achieved with both TGF-β1 and 5-azacytidine.

Conclusions:

• TGF-β1 can effectively induce cardiac differentiation in human bone marrow mesenchymal stem cells.
• TGF-β1 serves as a viable alternative to 5-azacytidine for cardiomyocyte differentiation.
• The study demonstrates comparable outcomes between TGF-β1 and 5-azacytidine in MSC cardiac differentiation.